Skip to content
Company Analysis

Rigel Pharmaceuticals, Inc. RIGL

A comprehensive view of key metrics, scores, and financial health for Rigel Pharmaceuticals, Inc.

Overview of Rigel Pharmaceuticals, Inc.

RIGL NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Small Cap
Rigel Pharmaceuticals, Inc. (RIGL), is a Small Cap company, in the Biotechnology industry, last closed at $50.53, about 19.2% overvalued vs fair value, +39.9% 1Y return, placing in the top 25% of its sector.
Metrics P/E 2.2× Rev Growth 64.1% ROE 185.9% Gross Margin 93.3%
USD 50.53
-1.52%
(Delayed)
• Vol 90d: 38.6%
52-Week Range
Market Cap
$943.89M
Enterprise Value
$922.31M
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Good
Valuation
Fair
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Good
Valuation
Fair
Completeness: 88%
Confidence: 92%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.rigel.com
HQ South San Francisco, CA
Employees 162
Fiscal year Dec 31

Next Events

Earnings Nov 5 Call: Nov 5

Fair Value Snapshot

Bear Base Bull
$38
$41
$44
Current: $50.53 -19% vs base

Engine Room Money Flow™

Small Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$40.6M
-28.5%%
Total Revenue
$294.3M
64.1%%
Net Income
$367.0M
1999.1%%
Operating Expense
$149.2M
9.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

R&D Intensity
22.3%
Poor

Low R&D intensity for a biotech - potential concern

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
1/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Rigel Pharmaceuticals, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
76
/100
Strong
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.90), demonstrating pricing resilience across cycles.
  • Cost Leadership Position Operating margin at 97.0th percentile with strong OpEx control demonstrates cost leadership.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.28), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
81
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger

Where management spends the performance budget

Insufficient Data for Analysis

RIGL - Rigel Pharmaceuticals, Inc.

We have limited financial data for RIGL. The Growth and Profitability axes don't have enough metrics for reliable analysis.

Data Coverage by Axis

Growth
0% coverage Below threshold
Profitability
0% coverage N/A
Overall Coverage: 33.3% (Minimum 40% required)

What This Means

  • Currently at 33.3% data coverage (minimum 40% required)
  • Limited peer data available for industry benchmarking
  • Check back after quarterly or annual filings
  • Some metrics may not be applicable to this company's business model

What can you do?

  • View available sections like Moat Map or Engine Room for partial insights
  • Set up a watchlist alert to be notified when new data becomes available
  • Compare with peers in the same industry that have complete data

Two Futures

Scenario-based fair value ranges for Rigel Pharmaceuticals, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$40.84
- - -
-19.2% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000